10-KPeriod: FY1998

BECTON DICKINSON & CO Annual Report, Year Ended Sep 30, 1998

Filed December 16, 1998For Securities:BDX

Summary

Becton Dickinson & Co. (BDX) filed its 10-K annual report for the fiscal year ended September 29, 1998. This filing provides a comprehensive overview of the company's financial performance, business operations, and strategic direction. As a leading medical technology company, BDX's performance in this period is critical for understanding its trajectory and market position. Investors should pay close attention to revenue growth, profitability, and any significant investments or acquisitions that may shape its future. The report highlights BDX's commitment to innovation and expanding its product portfolio across its key business segments. The company's focus on healthcare needs, such as infection control and diagnostics, positions it to benefit from demographic trends and increased healthcare spending. Understanding the company's strategy for organic growth and potential M&A activity will be key for assessing its long-term value creation potential.

Key Highlights

  • 1Fiscal year ended September 29, 1998.
  • 2BDX is a global leader in medical technology, focusing on key healthcare needs.
  • 3The report covers the company's financial performance and business operations for the fiscal year.
  • 4Key areas of focus likely include product innovation and market expansion.
  • 5Investors can gain insights into BDX's strategic direction and competitive landscape.
  • 6The filing provides a look at the company's product lines and their contribution to revenue.
  • 7This 10-K serves as a foundational document for understanding BDX's position in the medical technology market at the close of fiscal year 1998.

Frequently Asked Questions

Becton Dickinson & Co. is a global leader in medical technology, focused on improving the world's health by providing innovative solutions that help advance medical research, diagnostics, and patient care. Their products and services are used in healthcare institutions, life sciences research facilities, and other settings.

This 10-K filing typically includes audited financial statements (balance sheets, income statements, cash flow statements), management's discussion and analysis of financial condition and results of operations, details on the company's business segments, risk factors, legal proceedings, and information about executive compensation.

This date signifies the conclusion of the company's operating and financial reporting year for 1998. The 10-K report provides a retrospective look at the company's performance and financial standing as of and for this period.

Based on BDX's historical business, the key segments typically include BD Medical, BD Biosciences, and BD Diagnostics, which encompass a wide range of products from medical devices and laboratory equipment to diagnostic systems.